« Back to Medicines list

Chirocaine 1.25mg/ml solution for infusion

  • Name:

    Chirocaine 1.25mg/ml solution for infusion

  • Company:
    info
  • Active Ingredients:

    levobupivacaine hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/08/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 24/7/2019

Click on this link to Download PDF directly

AbbVie Limited

AbbVie Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Chirocaine 1.25mg/ml solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Chirocaine 2.5 mg/ml solution for injection/concentrate for solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Chirocaine 7.5 mg/ml solution for injection/concentrate for solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Duodopa intestinal gel Active Ingredients Carbidopa Monohydrate, Levodopa
Medicine Name Humira 20 mg solution for injection in pre-filled syringe Active Ingredients adalimumab
Medicine Name Humira 40 mg solution for injection in pre-filled syringe Active Ingredients adalimumab
Medicine Name Humira 40mg solution for injection in pre-filled pen Active Ingredients adalimumab
Medicine Name Humira 80 mg solution for injection in pre-filled pen Active Ingredients adalimumab
Medicine Name Kaletra 200 mg/50 mg film-coated tablets Active Ingredients Lopinavir, Ritonavir
Medicine Name Kaletra oral solution Active Ingredients Lopinavir, Ritonavir
Medicine Name Maviret 100 mg-40 mg film-coated tablets Active Ingredients Glecaprevir, Pibrentasvir
Medicine Name Norvir 100 mg powder for oral suspension Active Ingredients Ritonavir
Medicine Name Norvir 100mg Film-coated Tablets Active Ingredients Ritonavir
Medicine Name RINVOQ 15 mg prolonged-release tablets Active Ingredients Upadacitinib
Medicine Name Sevorane Active Ingredients Sevoflurane
Medicine Name Skyrizi 75 mg solution for injection in pre-filled syringe Active Ingredients Risankizumab
Medicine Name Synagis Solution for Injection Active Ingredients Palivizumab
Medicine Name Venclyxto 10mg, 50mg and 100mg Film-coated Tablets Active Ingredients Venetoclax
Medicine Name Zemplar 5 microgram/ml Solution for Injection Active Ingredients Paricalcitol
Medicine Name Zemplar capsules, soft Active Ingredients Paricalcitol
1 - 0 of 21 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12 August 2019 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 24 July 2019 PIL

Reasons for updating

  • Change to section 2 - excipient warnings

Updated on 24 July 2019 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 18 July 2018 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 July 2018 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Description of change

 

SmPC was updated to reflect approval of Type IB Label alignment for Chirocaine 1.25 mg/ml solution for infusion.

 

The following is summary of the changes:

 

The Summary of Product Characteristics title has been added in line with QRD

 

4.1     Therapeutic indications

Minor editorial update.

 

4.2     Posology and method of administration

Minor editorial updates.

 

4.4     Special warnings and precautions for use

Minor editorial updates.

 

4.5     Interaction with other medicinal products and other forms of interaction

Minor editorial updates.

 

4.6     Fertility, pregnancy and lactation

Minor editorial update.

 

4.8     Undesirable effects

Minor editorial updates.

 

10.       Date of Revision of Text

Update to July 2018.

Updated on 9 July 2018 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Description of change

 

SmPC was updated to reflect approval of Type IB Label alignment for Chirocaine 1.25 mg/ml solution for infusion.

 

The following is summary of the changes:

 

The Summary of Product Characteristics title has been added in line with QRD

 

4.1     Therapeutic indications

Minor editorial update.

 

4.2     Posology and method of administration

Minor editorial updates.

 

4.4     Special warnings and precautions for use

Minor editorial updates.

 

4.5     Interaction with other medicinal products and other forms of interaction

Minor editorial updates.

 

4.6     Fertility, pregnancy and lactation

Minor editorial update.

 

4.8     Undesirable effects

Minor editorial updates.

 

10.       Date of Revision of Text

Update to July 2018.

Updated on 16 November 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 16 November 2016 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 25 January 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 25 January 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 25 January 2016 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to MA holder contact details

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7: Marketing Holder Authorisation:

Update to MAH address

Updated on 18 November 2015 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 7 August 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 22 June 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 To update Section 4.4 of the SmPC to include adverse drug reaction of chondrolysis in patients receiving post-operative intra-articular continuous infusion of local anaesthetics.

Updated on 19 February 2015 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 & Section 4.2

No data are available in paediatric population < 6 months of age.

 

 

Section 4.8

Information on how to report an AE in Ireland.



New individual SPC

Updated on 18 February 2015 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 11 July 2013 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 29 April 2013 PIL

Reasons for updating

  • Change of manufacturer

Updated on 11 December 2012 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 11 December 2012 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 16 November 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 4 November 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 5 July 2010 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 7 December 2009 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 7 October 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 26 June 2009 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 9 February 2009 PIL

Reasons for updating

  • Addition of separate PILs covering individual presentations
  • Change due to harmonisation of patient information leaflet
  • Change due to user-testing of patient information

Updated on 1 June 2005 PIL

Reasons for updating

  • New PIL for medicines.ie